First patients dosed in early trial of promising new cancer drug

NCT ID NCT07181473

Summary

This is the first-ever study in people of an experimental cancer drug called TJ101. The main goal is to find a safe dose and see how the body handles it. The study will also look for early signs that the drug can shrink tumors in adults with advanced cancers who have run out of standard treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Cancer Specialists & Research Institute

    RECRUITING

    Orlando, Florida, 32827, United States

    Contact Phone: •••-•••-••••

  • Henan Cancer Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oncology Consultants

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon Research Institute (SCRI)

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-••••

  • Shanghai East Hospital

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Sir Run Run Shaw Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Union Hospital of Tongji Medical College

    NOT_YET_RECRUITING

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.